From bench to patient care: unlocking iPSC potential through innovative science and strategic partnerships
Leveraging science and partnerships to accelerate the journey from iPSC line to patient care.
In the iPSC-derived cell therapy field, developing a suitable iPSC line is a key step, but not the only one. Accessing a GMP iPSC line for clinical and commercial use, gene editing methods, securing efficient differentiation and/or expansion protocols, bringing them to scale and ensuring GMP manufacturing from early clinic to late stage, including optimal analytical testing and patent coverage, are all key steps a biotech will need to cross. This webinar will discuss the challenges faced in bringing iPSC-derived cell therapy from bench to patients, the solutions Catalent Pharma Solutions (NJ, USA) offers and how global partnerships can accelerate the journey from innovation to patient care.
What will you learn?
-
iPSCs: the promise of a new wave of advanced cell therapies
-
Speed to clinic with GMP iPSC cell lines
-
GMP-compatible gene editing and differentiation methodologies
-
Novel differentiation platform for immune cells, iNK, iRPE, iMSCs and cardiac cells
-
Partnerships that may accelerate the journey from bench to clinic and commercialization by accessing platforms, IP and ‘Know-How’
Who this may interest?
- Cell therapy developers
- Emerging Biopharma
- Pharma using iPSCs
Speakers
Boris Greber
Head of Research and Development, iPSC/CT
Catalent Pharma Solutions (Dusseldorf, Germany)
Boris Greber is the Head of R&D, iPSC at Catalent Cell & Gene therapy in Europe. He joined Catalent as part of the RheinCell Therapeutics acquisition. He previously served as an independent research group leader at the Max Planck Institute for Molecular Biomedicine (Münster, Germany). Boris is internationally recognized with a 15-year track record in basic and applied human iPSC research.
Anthony Caputi
Account Executive, iPSC & Cell Therapy Division
Catalent Pharma Solutions (NJ, USA)
Anthony is an Account Executive for Catalent’s Plasmid, iPSC and Cell Therapy division where he is responsible for developing business growth for North America through strategic customer partnerships.
Anthony has 6+ years of experience in the CDMO and cell and gene therapy business development space successfully supporting GMP Operations, Supply Chain, Proposal Development, Program Management, Continuous Improvement and Business Development teams and activities. Anthony holds a Master’s and Bachelor’s degree in Chemical Engineering from Drexel University (PA, USA).
This webinar was recorded on Tuesday 11 March 2025
In association with
